NFKB1 and breast carcinoma: Furthermore, inhibition of NF-κB/p65 with dehydroxymethylepoxyquinomicin (DHMEQ) decreased migration and invasion in human breast cancer cell lines, MDA-MB-231 and HCC-1954 [30].